MENLO PARK, Calif., Jan. 29, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leader in high-quality, long-read sequencing, is proud to announce its critical role in a study to be published in ...
There is major uncertainty regarding research funding now, and while usage trends for PacBio's systems are good, the reality is that these are expensive machines and this is not a good time to be ...
Earnings Call Insights: Pacific Biosciences of California, Inc. (NASDAQ:PACB) Q4 2024 CEO Christian Henry highlighted Q4 2024 revenue of $39.2 million, driven by the shipment of 23 Revio systems ...
Loss on extinguishment of debt is related to the exchange of a portion of PacBio's 1.50% Convertible Senior Notes due 2028 for PacBio's 1.375% Convertible Senior Notes due 2030. Gain on debt ...
20:11 EST Cathie Wood’s ARK Investment bought 344K shares of PacBio (PACB) today Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and ...
Hosted on MSN1mon
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Q4 2024 Earnings Call TranscriptPacific Biosciences of California, Inc. (NASDAQ:PACB) Q4 2024 Earnings Call Transcript February 13, 2025 Pacific Biosciences of California, Inc. beats earnings expectations. Reported EPS is $0.51 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback